These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6781737)

  • 1. Mode of inhibition of tumor cell ribonucleotide reductase by 2,3-dihydro-1H-pyrazolo[2,3-a]imidazole (NSC 51143).
    Cory JG; Fleischer AE
    Cancer Res; 1980 Nov; 40(11):3891-4. PubMed ID: 6781737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies on mammalian ribonucleotide reductase inhibition by pyridoxal phosphate and the dialdehyde derivatives of adenosine, adenosine 5'-monophosphate, and adenosine 5'-triphosphate.
    Cory JG; Mansell MM
    Cancer Res; 1975 Feb; 35(2):390-6. PubMed ID: 1109803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron and haem complexation studies of 2,3-dihydro-1H-imidazo(1,2-b)pyrazole (IMPY, NSC 51143), a tumour cell ribonucleotide reductase inhibitor.
    Ahmet MT; Douglas KT; Silver J; Goddard AJ; Wilman DE
    Anticancer Drug Des; 1986 Nov; 1(3):189-95. PubMed ID: 3329911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ribonucleotide reductase activity and nucleic acid synthesis in tumor cells by the dialdehyde derivatives of inosine (NSC 118994) and inosinic acid.
    Cory JG; Mansell MM; Whitford TW
    Cancer Res; 1976 Sep; 36(9 pt.1):3166-70. PubMed ID: 987850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of combinations of drugs that inhibit Ehrlich tumor cell ribonucleotide reductase.
    Sato A; Cory JG
    Cancer Res; 1981 May; 41(5):1637-41. PubMed ID: 6783298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and ribonucleotide reductase inhibitory activity of analogues of 2,3-dihydro-1H-imidazo[1,2-b]pyrazole (IMPY).
    Goddard AJ; Orr RM; Stock JA; Wilman DE
    Anticancer Drug Des; 1987 Dec; 2(3):235-45. PubMed ID: 3329526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the cytidine 5'-diphosphate and adenosine 5'-diphosphate reductase activities of mammalian ribonucleotide reductase.
    Cory JG; Mansell MM
    Cancer Res; 1975 Sep; 35(9):2327-31. PubMed ID: 167952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea-induced conversion of mammalian ribonucleotide reductase to a form hypersensitive to bleomycin.
    McClarty GA; Chan AK; Wright JA
    Cancer Res; 1986 Sep; 46(9):4516-21. PubMed ID: 2425956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of mammalian ribonucleotide reductase by a dinucleotide produced in eucaryotic cells.
    Lewis WH; McNaughton DR; Goh SH; LéJohn HB; Wright JA
    J Cell Physiol; 1977 Dec; 93(3):345-52. PubMed ID: 338619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Specific inhibitors directed at the individual components of ribonucleotide reductase as an approach to combination chemotherapy.
    Cory JG; Fleischer AE
    Cancer Res; 1979 Nov; 39(11):4600-4. PubMed ID: 498090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Studies on the differential mechanisms of inhibition of ribonucleotide reductase by specific inhibitors of the non-heme iron subunit.
    Sato A; Bacon PE; Cory JG
    Adv Enzyme Regul; 1984; 22():231-41. PubMed ID: 6089512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Substrate specificity of human ribonucleotide reductase from Molt-4F cells.
    Chang CH; Cheng YC
    Cancer Res; 1979 Dec; 39(12):5081-6. PubMed ID: 498135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The utility of combinations of drugs directed at specific sites of the same target enzyme--ribonucleotide reductase as the model.
    Cory JG; Sato A; Carter GL; Bacon PE; Montgomery JA; Brown NC
    Adv Enzyme Regul; 1985; 23():181-92. PubMed ID: 3907303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential substrate properties of mammalian ribonucleotide reductase.
    Cory JG; Cory AH; Downes DL
    Adv Exp Med Biol; 1994; 370():631-5. PubMed ID: 7660984
    [No Abstract]   [Full Text] [Related]  

  • 16. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combinations of drugs having different modes of action at the ribonucleotide reductase site on growth of L1210 cells in culture.
    Sato A; Carter GL; Bacon PE; Cory JG
    Cancer Res; 1982 Nov; 42(11):4353-7. PubMed ID: 6751522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 8-Azidoadenosine and ribonucleotide reductase.
    Roy B; Lepoivre M; Decout JL; Lhomme J; Fontecave M
    Biochem Biophys Res Commun; 1992 Aug; 187(1):432-7. PubMed ID: 1520331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2,2'-Bipyridyl-6-carbothioamide and its ferrous complex: their in vitro antitumoral activity related to the inhibition of ribonucleotide reductase R2 subunit.
    Nocentini G; Federici F; Franchetti P; Barzi A
    Cancer Res; 1993 Jan; 53(1):19-26. PubMed ID: 8416745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.